Identifying Prostatic Utricle Translucent Membrane in Hematospermia Patients Using a Novel Nomogram.

Hematospermia, characterized by blood in the ejaculate, is a common and distressing condition in urology. Identifying the underlying causes, including translucent membranes in the prostatic utricle, is crucial for effective management. Despite advancements in diagnostic techniques, reliable predictive tools are needed to enhance preoperative planning and patient outcomes. This study aimed to develop a novel nomogram to predict the presence of translucent membranes in the prostatic utricle of hematospermia patients. In total, 284 patients were selected from The Second People's Hospital of Hefei database based on inclusion and exclusion criteria. The cohort was divided into a training set (198 patients) and a validation set (86 patients). To identify risk factors associated with the prostatic utricle translucent membrane, multivariable logistic regression analysis was employed. The identified risk factors were then used to construct a predictive nomogram model. The performance of the nomogram was evaluated using several statistical tools: receiver operating characteristic (ROC) curves to assess discriminative ability, calibration curves to evaluate prediction accuracy, and decision curve analysis (DCA) to determine clinical utility. The findings revealed that age, duration of disease, history of seminal vesiculitis, and seminal vesicle dimensions (width, length, and thickness) were independent risk factors for the presence of a prostatic utricle translucent membrane in patients with hematospermia. Using these variables, a nomogram was developed. The nomogram demonstrated strong predictive capability, as evidenced by its performance in ROC and calibration curve analyses. Furthermore, the DCA indicated that the nomogram offered significant clinical net benefits in predicting the presence of a translucent membrane. Clinical use of the developed nomogram can assist clinicians in identifying patients with hematospermia who have translucent membrane in the prostatic utricle and in developing individualized treatment.